W.E. Donoghue & Co. LLC acquired a new stake in Celgene Co. (NASDAQ:CELG) in the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor acquired 26,572 shares of the biopharmaceutical company’s stock, valued at approximately $2,456,000.
Other hedge funds have also added to or reduced their stakes in the company. Archford Capital Strategies LLC raised its holdings in Celgene by 277.8% in the 1st quarter. Archford Capital Strategies LLC now owns 272 shares of the biopharmaceutical company’s stock valued at $26,000 after acquiring an additional 200 shares during the last quarter. Investors Research Corp acquired a new stake in Celgene in the 1st quarter valued at about $28,000. Liberty Wealth Management LLC acquired a new stake in Celgene in the 4th quarter valued at about $29,000. Weaver Consulting Group acquired a new stake in Celgene in the 1st quarter valued at about $29,000. Finally, Alera Investment Advisors LLC raised its holdings in Celgene by 109.9% in the 1st quarter. Alera Investment Advisors LLC now owns 319 shares of the biopharmaceutical company’s stock valued at $30,000 after acquiring an additional 167 shares during the last quarter. Institutional investors own 74.84% of the company’s stock.
Shares of NASDAQ:CELG traded up $0.82 during mid-day trading on Friday, reaching $93.87. 4,136,416 shares of the company were exchanged, compared to its average volume of 3,618,393. The company has a debt-to-equity ratio of 1.97, a quick ratio of 2.66 and a current ratio of 3.44. The company has a market cap of $66.53 billion, a price-to-earnings ratio of 12.34, a price-to-earnings-growth ratio of 0.43 and a beta of 1.46. The company has a 50-day moving average price of $93.40. Celgene Co. has a 1 year low of $58.59 and a 1 year high of $98.97.
CELG has been the subject of a number of recent research reports. BidaskClub upgraded shares of Celgene from a “strong sell” rating to a “sell” rating in a report on Saturday. Cantor Fitzgerald downgraded shares of Celgene from an “overweight” rating to a “neutral” rating and set a $94.00 price target for the company. in a report on Friday, April 5th. Barclays downgraded shares of Celgene from an “overweight” rating to an “equal weight” rating and set a $102.00 price target for the company. in a report on Friday, May 3rd. Cowen restated a “hold” rating and set a $102.00 price target on shares of Celgene in a report on Tuesday. Finally, Zacks Investment Research upgraded shares of Celgene from a “sell” rating to a “hold” rating and set a $94.00 price target for the company in a report on Tuesday, July 23rd. Two equities research analysts have rated the stock with a sell rating, sixteen have assigned a hold rating and four have issued a buy rating to the stock. The company presently has an average rating of “Hold” and a consensus price target of $94.81.
Celgene Corporation, a biopharmaceutical company, discovers, develops, and commercializes therapies for the treatment of cancer and inflammatory diseases worldwide. It offers REVLIMID, an oral immunomodulatory drug for multiple myeloma (MM), myelodysplastic syndromes (MDS), and mantle cell lymphoma; POMALYST/IMNOVID to treat multiple myeloma; OTEZLA, a small-molecule inhibitor of phosphodiesterase 4 for psoriatic arthritis and psoriasis; and ABRAXANE to treat breast, non-small cell lung, pancreatic, and gastric cancers.
Featured Story: Price to Earnings Ratio (PE)
Receive News & Ratings for Celgene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celgene and related companies with MarketBeat.com's FREE daily email newsletter.